

Geoffrey S Ginsburg MD, PHD
Professor of Medicine,
Pathology, and Biomedical
Engineering
Duke University

@PersonalizedMed



May 7, 2020



A National Network for Implementing **GeN**omics In prac**TicE**: **IGNITE**



IGNITE
www.ignite-genomics.org

**The Duke Center for Applied Genomics
& Precision Medicine**
precisionmedicine.duke.edu



Global Genomic
Medicine Collaborative

A black and white photograph of a rugged, mountainous landscape. The foreground is dark and rocky, leading up to a series of rolling hills and mountains. Patches of snow or light-colored rock are visible on the slopes. The sky is overcast with soft, grey clouds. The overall mood is somber and atmospheric.

**Vision Without
Implementation is
Hallucination**

--Thomas Edison--



Early Precision Medicine: 1961 “Factors of Risk”

Annals of Internal Medicine

Established in 1927 by the American College of Physicians

Factors of Risk in the Development of Coronary Heart Disease—Six-Year Follow-up Experience

Kannel WB et al.

November 1961

- High blood pressure
- Increased cholesterol
- HDL cholesterol
- Smoking
- Diabetes
- Family history
- Male sex

Source: Kannel WB et al. *Ann Intern Med* 1961;55:33–50.



> 50 Years Later: Failure of Implementation of CVD Risk Calculators



- Primary Care Physicians
 - only 13% had read guidelines carefully
 - only 17% used a CHD risk calculator

“a large variability in knowledge, beliefs, and practice patterns among practicing family physicians”

- Barriers
 - Lack of knowledge
 - Distrust in validity
 - Time consuming

Eaton CB, *J Am Board Fam Med* 2006; 19:46–53.
Eichler K, *BMC Fam Pract* 2007; 8:1.


Genomics Translation: Funding Has Not Been A Priority for Implementation (USA)



Puggal, Circ Cardiovasc Genet. 2013



Not All Payers are Alike





Payer Adoption of Oncotype DX®

COVERAGE INCONSISTENCIES FOR SAMPLE DIAGNOSTICS (2010)*

Innovative Test Examples	FDA Cleared?	Positive Coverage Policies			
		Aetna	Regional CMS	Cigna	Regional BCBS
AlloMap	Yes		✓		
Oncotype DX (breast Cancer)	No	✓	✓	✓	✓
MammaPrint	Yes		✓		
Pathwork Tissue of Origin	Yes				
BRACAnalysis	No	✓	✓	✓	✓
OVA1	Yes		✓		✓
KRAS (colorectal cancer)	No	✓	✓	✓	✓

*Note: All of these tests are offered as LDTs. The information in this table was current as of the publication of the source report in 2010, and has not been updated to reflect the most current information.

Source: BIO and Health Advances Report: The Reimbursement Landscape for Novel Diagnostics: Current Limitations, Real-World Impact, and Proposed Solutions. 2010.

Article

Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer

Christine Y. Lu ^{1,*}, Stephanie Loomer ¹, Rachel Ceccarelli ¹, Kathleen M. Mazor ², James Sabin ³, Ellen Wright Clayton ⁴, Geoffrey S. Ginsburg ⁵ and Ann Chen Wu ¹



The IGNITE Network (NHGRI)

Weitzel et al. *BMC Medical Genomics* (2016) 9:1
DOI 10.1186/s12920-015-0162-5

BMC Medical Genomics

RESEARCH ARTICLE

Open Access

The IGNITE network: a model for genomic medicine implementation and research



Kristin Wiisanen Weitzel¹, Madeline Alexander², Barbara A. Bernhardt³, Neil Calman⁴, David J. Carey⁵, Larisa H. Cavallari¹, Julie R. Field⁶, Diane Hauser⁴, Heather A. Junkins⁷, Phillip A. Levin⁸, Kenneth Levy⁹, Ebony B. Madden⁷, Teri A. Manolio⁷, Jacqueline Odgis⁷, Lori A. Orlando^{10,19}, Reed Pyeritz³, R. Ryanne Wu^{10,19}, Alan R. Shuldiner^{11,12}, Erwin P. Bottinger¹³, Joshua C. Denny^{14,15}, Paul R. Dexter⁹, David A. Flockhart⁹, Carol R. Horowitz¹⁶, Julie A. Johnson¹, Stephen E. Kimmel^{2,17}, Mia A. Levy¹⁸, Toni I. Pollin¹¹, Geoffrey S. Ginsburg^{19*} and on behalf of the IGNITE Network


- **Expand and link** existing genomic medicine efforts
- Develop **implementation** methods, in diverse settings and populations
- Contribute to **evidence** base regarding outcomes of incorporating genomic information into clinical care
- **Disseminate best practices** for genomic medicine implementation, diffusion, and sustainability



www.gmkb.org



- * IGNITE Principal Site
- ★ New sites




- Duke University – Geoffrey Ginsburg, M.D., Ph.D
Lori Orlando, M.D. (Family History and Coordinating Center)
- Mount Sinai School of Medicine – Carol Horowitz, M.D. (Hypertension and CKD)
- University of Florida – Julie Johnson, Ph.D. (Pharmacogenomics)
- National Human Genome Research Institute
- ★ Vanderbilt University – Joshua Denny, M.D., Josh Peterseon M.D. (Pharmacogenomics)
- ★ Indiana University – Todd Skaar, Ph.D., Paul Dexter, M.D. (Pharmacogenomics)

Risk Recommendations in ~ 2000 Unselected Patients (~ 25,000 Relatives) in 19 Primary Care Clinics

Risk Management Recommendations	N (%)
Monogenic Disorders Related Recommendations	597 (31.6%)
Genetic counseling for hereditary cardiac syndromes	107 (5.7%)
Genetic counseling for hereditary cancer syndromes	395 (20.1%)
Genetic counseling for hereditary thrombophilia	165 (8.7%)
Familial hypercholesterolemia testing	66 (3.4%)
Hemochromatosis iron studies and genetic testing	3 (0.2%)
Wilson's disease genetic testing	11 (0.6%)
Alpha 1 anti-trypsinase deficiency genetic testing	11 (0.6%)
Familial Cancer Related Recommendations	508 (26.9%)
Ovarian cancer screening discussion	32 (1.7%)
Breast MRI screening	58 (3.2%)
Breast cancer chemoprevention	109 (6%)
Colonoscopy screening starting age < 50 and/or more frequently	241 (13.1%)
Common Chronic Disease Related Recommendations	1059 (56.1%)
Aspirin for stroke prevention	67 (3.6%)
Diabetes screening	858 (45.4%)
Abdominal Aortic Aneurysm screening	389 (20.6%)
Calcium scoring CT for further cardiovascular risk stratification	11 (0.6%)
Lung cancer screening	45 (2.4%)

A significant percentage of the general primary care population meet criteria for more intensive risk management

The Power of the Network to Rapidly Implement and Assess Impact: CYP2C19 and Antiplatelet Rx






IGNITE I: The Realities of Genomic Medicine Research

- Implementation is a science and it is hard
 - Complex workflows must be understood
 - Process measures can optimize integration into patient/provider workflows
- EMRs are not ready to incorporate genomic data
- Local provider champions are key
- Network wide studies are enormously powerful
 - Genomic medicine research may also help reduce disparities




IGNITE II: Pragmatic Clinical Trials Network





A Depression and Opioid Pragmatic Trial in Pharmacogenetics (ADOPT PGx)

Determine whether genotype-guided therapy of opioids and SSRIs leads to improved acute and chronic pain control and depressive symptoms





ADOPT-PGx

A Depression and Opioid
Pragmatic Trial in Pharmacogenetics




Genetic testing to **Understand Renal Disease Disparities** across the U.S. (GUARDD-US)

To determine the effect of participant and provider knowledge of a positive *APOL1* status on blood pressure management on change in systolic blood pressure (SBP) from baseline to 3 months after randomization among the *APOL1+* participants (African Americans).



Things change in the real world and impact original study design





LMIC Opportunities

- Build clinical genomics capacity (clinical labs and workflows)
- Build competencies in genomics knowledge, communication, and decision making to create a vibrant genomics workforce
- Population literacy and numeracy should be a priority
- Diversity of practice across globe require different implementation solutions
- Engage the participants in solving the problems
- Need for collaboration

“G2MC can IGNITE the LMICs”

Teamwork

